Evidence map›Paper›PMID 35877180›Full record

ArticleDiabetes2022

Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice.

Teayoun Kim, Shelly Nason, Jessica Antipenko, Brian Finan, Anath Shalev, Richard DiMarchi, Kirk M Habegger

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Teayoun KimComprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Shelly NasonComprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Jessica AntipenkoComprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Brian FinanNovo Nordisk Research Center Indianapolis, Indianapolis, IN.
Anath ShalevComprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Richard DiMarchiDepartment of Chemistry, Indiana University, Bloomington, IN.
Kirk M HabeggerComprehensive Diabetes Center and Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.ORCID 0000-0002-0342-5480
University of Alabama at Birmingham · USIndiana University Bloomington · USNovo Nordisk (United States) · US

Funding

Why is the prevalence of obesity so high in U.S. Southern States? Regional predictors of BMI and obesity treatment response.P30DK056336 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BARBARA A GOWER · 2000 to 2026
$31.9M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
TXNIP REGULATION OF ENDOGENOUS BETA CELL MASSR01DK078752 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI SHALEV, ANATH · 2008 to 2021
$4.4M
Glucagon Mediated Potentiation of Insulin Sensitivity in Glucose MetabolismR01DK112934 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HABEGGER, KIRK MICHAEL · 2017 to 2021
$1.7M
NIDDK NIH HHS P30 DK056336NIDDK NIH HHS P30 DK079626NIDDK NIH HHS R01 DK078752NIDDK NIH HHS R01 DK112934
6 · The paper itself

Abstract

Long-term glucagon receptor (GCGR) agonism is associated with hyperglycemia and glucose intolerance, while acute GCGR agonism enhances whole-body insulin sensitivity and hepatic AKTSer473 phosphorylation. These divergent effects establish a critical gap in knowledge surrounding GCGR action. mTOR complex 2 (mTORC2) is composed of seven proteins, including RICTOR, which dictates substrate binding and allows for targeting of AKTSer473. We used a liver-specific Rictor knockout mouse (RictorΔLiver) to investigate whether mTORC2 is necessary for insulin receptor (INSR) and GCGR cross talk. RictorΔLiver mice were characterized by impaired AKT signaling and glucose intolerance. Intriguingly, RictorΔLiver mice were also resistant to GCGR-stimulated hyperglycemia. Consistent with our prior report, GCGR agonism increased glucose infusion rate and suppressed hepatic glucose production during hyperinsulinemic-euglycemic clamp of control animals. However, these benefits to insulin sensitivity were ablated in RictorΔLiver mice. We observed diminished AKTSer473 and GSK3α/βSer21/9 phosphorylation in RictorΔLiver mice, whereas phosphorylation of AKTThr308 was unaltered in livers from clamped mice. These signaling effects were replicated in primary hepatocytes isolated from RictorΔLiver and littermate control mice, confirming cell-autonomous cross talk between GCGR and INSR pathways. In summary, our study reveals the necessity of RICTOR, and thus mTORC2, in GCGR-mediated enhancement of liver and whole-body insulin action.

Indexed as

Glucose IntoleranceHyperglycemiaInsulin ResistanceAnimalsGlucoseHomeostasisInsulinInsulin, Regular, HumanLiverMechanistic Target of Rapamycin Complex 2MiceMice, Inbred C57BLMice, KnockoutProto-Oncogene Proteins c-aktRapamycin-Insensitive Companion of mTOR ProteinReceptor, InsulinGlucoseInsulinInsulin, Regular, HumanMechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins c-aktRapamycin-Insensitive Companion of mTOR ProteinReceptor, InsulinReceptors, Glucagonrictor protein, mouseTOR Serine-Threonine Kinases

Identifiers

PMID35877180
PMCPMC9501720
OpenAlexW4287447321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.